Hui Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hui Zhang has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Guosong Jiang
Department of Urology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China
16 shared publications - Chao Huang
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
15 shared publications - Xincheng Gao
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
15 shared publications - Huayuan Zhao
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
14 shared publications - Jiayin Sun
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
14 shared publications - Junping Li
Department of Urology, Guangdong Second Provincial General Hospital, Guangzhou, China
14 shared publications
Latest Publications
- Open Access
- 25 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 3824
CircPRKCA Promotes NSCLC Progression via miR-200b-3p/FRMD6/SNAI2 Axis
Circular RNAs (circRNAs) have been reported to be closely associated with tumor progression in multiple malignancies. However, the specific mechanism by which circPRKCA influences tumor progression has not been fully elucidated. CircPRKCA is highly expressed in non-small cell lung cancer (NSCLC) tissues and cells. Knockdown of circPRKCA inhibits the malignant behaviors of NSCLC cells. RNA sequencing results revealed that FRMD6 and SNAI2 mRNAs are positively correlated with circPRKCA. Subsequently, we proved that circPRKCA acts as a molecular sponge for miR-200b-3p. Additionally, miR-200b-3p binds to the 3′ untranslated regions (3′UTRs) of FRMD6 and SNAI2 mRNAs to promote their degradation. Overexpression of circPRKCA thereby suppresses this degradation process and coun-teracts the tumor-suppressive effects induced by miR-200b-3p. CircPRKCA functions as the sponge of miR-200b-3p, suppressing the SNAI2/FRMD6 mRNA degradation driven by miR-200b-3p and accelerating NSCLC progression.
- 25 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 3824
Open AccessCircPRKCA Promotes NSCLC Progression via miR-200b-3p/FRMD6/SNAI2 Axis
Circular RNAs (circRNAs) have been reported to be closely associated with tumor progression in multiple malignancies. However, the specific mechanism by which circPRKCA influences tumor progression has not been fully elucidated. CircPRKCA is highly expressed in non-small cell lung cancer (NSCLC) tissues and cells. Knockdown of circPRKCA inhibits the malignant behaviors of NSCLC cells. RNA sequencing results revealed that FRMD6 and SNAI2 mRNAs are positively correlated with circPRKCA. Subsequently, we proved that circPRKCA acts as a molecular sponge for miR-200b-3p. Additionally, miR-200b-3p binds to the 3′ untranslated regions (3′UTRs) of FRMD6 and SNAI2 mRNAs to promote their degradation. Overexpression of circPRKCA thereby suppresses this degradation process and coun-teracts the tumor-suppressive effects induced by miR-200b-3p. CircPRKCA functions as the sponge of miR-200b-3p, suppressing the SNAI2/FRMD6 mRNA degradation driven by miR-200b-3p and accelerating NSCLC progression.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Effects of DMSO, MCHA, Erdafitinib and combined treatment on the indicators of cardiac, hepatic, and renal function of mice.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Effects of DMSO, MCHA, Erdafitinib and combined treatment on the indicators of cardiac, hepatic, and renal function of mice.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementay Table 1 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
The sequences of primers used in this study.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementay Table 1 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
The sequences of primers used in this study.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S5 shows that HMGA2 directly binds to the promoter of EGFR.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S5 shows that HMGA2 directly binds to the promoter of EGFR.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Determination of the protein potentially regulated by SRM using Venn analysis.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Determination of the protein potentially regulated by SRM using Venn analysis.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S7 shows that SRM inhibitor MCHA is synthetic lethal with Erdafitinib.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S7 shows that SRM inhibitor MCHA is synthetic lethal with Erdafitinib.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S2 shows that SRM loss enhances erdafitinib efficacy in bladder cancer.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S2 shows that SRM loss enhances erdafitinib efficacy in bladder cancer.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S4 shows that SRM supports the efficient translation of HMGA2 by eIF5A hypusination.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S4 shows that SRM supports the efficient translation of HMGA2 by eIF5A hypusination.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementay Table 2 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
The sequences of shRNA and sgRNA used in this study.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementay Table 2 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
The sequences of shRNA and sgRNA used in this study.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Identification of synthetic lethal genes for erdafitinib in MGH-U3 and SW780 cells using Venn analysis.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Identification of synthetic lethal genes for erdafitinib in MGH-U3 and SW780 cells using Venn analysis.